Sam Brusco, Associate Editor08.25.23
GE HealthCare has launched CardioVisio for atrial fibrillation (AFib), a digital tool to help visualize longitudinal data relevant for disease progression from multiple data sources, and driving evidence-based clinical decision support directed by up-to-date AFib guidelines.
The new tech will be showcased at the European Society of Cardiology Congress 2023 from August 25-28.
“Existing diagnosis and treatment care models for AFib have been shown to be complex, time consuming and disconnected with disparate guidelines and poor guideline adherence,” Eigil Samset, PhD, general manager, Cardiology Solutions, GE HealthCare told the press. “With CardioVisio for AFib, we’re providing cardiologists with a powerful tool that streamlines clinician image interpretation and provides a view of the history of the patient’s heart as well as their healthcare journey, including previous diagnoses, prescribed medications, interventions, and comorbidities.”
CardioVisio, according to GE HealthCare, can help save time and aid clinical decision making by providing guideline-directed therapy recommendations. Each automated step includes explainability and traceability, so healthcare providers can audit and edit the process and output to meet the needs of each AFib patient.
“Our busy clinicians face a multitude of disparate patient data generated from years of diagnostic exams, medications, medical appointments, and interventions,” said Dr. Kenneth Civello, Electrophysiologist and Cardiologist with Louisiana Cardiology Associates at Our Lady of the Lake Physician Group. “CardioVisio for AFib incorporates algorithms that intake available relevant data as triggers for industry-published guidelines which can help ease the burden of data overload on our staff and will enable us as healthcare providers to provide timelier, personalized and evidence-based care to our patients.”
CardioVisio AFib is now available in the U.S., and the company aims to expand availability in the coming months.
The new tech will be showcased at the European Society of Cardiology Congress 2023 from August 25-28.
“Existing diagnosis and treatment care models for AFib have been shown to be complex, time consuming and disconnected with disparate guidelines and poor guideline adherence,” Eigil Samset, PhD, general manager, Cardiology Solutions, GE HealthCare told the press. “With CardioVisio for AFib, we’re providing cardiologists with a powerful tool that streamlines clinician image interpretation and provides a view of the history of the patient’s heart as well as their healthcare journey, including previous diagnoses, prescribed medications, interventions, and comorbidities.”
CardioVisio, according to GE HealthCare, can help save time and aid clinical decision making by providing guideline-directed therapy recommendations. Each automated step includes explainability and traceability, so healthcare providers can audit and edit the process and output to meet the needs of each AFib patient.
“Our busy clinicians face a multitude of disparate patient data generated from years of diagnostic exams, medications, medical appointments, and interventions,” said Dr. Kenneth Civello, Electrophysiologist and Cardiologist with Louisiana Cardiology Associates at Our Lady of the Lake Physician Group. “CardioVisio for AFib incorporates algorithms that intake available relevant data as triggers for industry-published guidelines which can help ease the burden of data overload on our staff and will enable us as healthcare providers to provide timelier, personalized and evidence-based care to our patients.”
CardioVisio AFib is now available in the U.S., and the company aims to expand availability in the coming months.